Il17a - interleukin 17A Gene

Also Known as Il17; IL-17; CTLA-8; IL-17A

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 301289

About Il17a

Primary_assembly 9: 23,144,402-23,147,889 forward strand.mRatBN7.2:CM026982.1

This gene has 1 transcript (splice variant), 97 orthologues, 4 paralogues and is associated with 105 phenotypes. Low expression observed in reference dataset.

Summary

Predicted to enable protein heterodimerization activity and protein homodimerization activity. Involved in several processes, including cellular response to glucocorticoid stimulus; positive regulation of necrotic cell death; and positive regulation of transcription by RNA polymerase II. Located in cytoplasm and extracellular space. Used to study anti-basement membrane glomerulonephritis; congestive heart failure; myocarditis; pleurisy; and uveitis. Biomarker of several diseases, including acute necrotizing pancreatitis; inflammatory bowel disease (multiple); lipoid nephrosis; lung disease (multiple); and periodontal disease (multiple). Human ortholog(s) of this gene implicated in Mycobacterium avium complex disease; autoimmune disease (multiple); bronchial disease (multiple); macular degeneration; and rhinitis (multiple). Orthologous to human IL17A (interleukin 17A). [provided by Alliance of Genome Resources, Apr 2022]

Il17a Products (1)

mRNA Protein Name
NM_001106897.1 NP_001100367.1 interleukin-17A precursor

Gene Ontology

  • Biological Process
  • Cellular Component
Biological Process GO Annotation Evidence References Source
involved in cellular response to glucocorticoid stimulus IMP
IMP: Inferred from mutant phenotype
20003332 RGD
involved in positive regulation of transcription by RNA polymerase II IDA
IDA: Inferred from direct assay
22990529 RGD
involved in response to amino acid IEP
IEP: Inferred from expression pattern
22673595 RGD
Cellular Component GO Annotation Evidence References Source
located in extracellular space IDA
IDA: Inferred from direct assay
21043049 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Il17a Protein Structure

IL17

IL17: pfam06083 (71 - 149)

  • 0
  • 100
  • 158 a.a.
Protein Preferred Names Protein Names

interleukin-17A

  • Interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8)

  • cytotoxic T-lymphocyte-associated antigen 8

Recombinant Il17a Proteins

Cat. No. Product Name Accession Purity
HY-P79326 IL-17A Protein, Rat (CHO) G3V7M4/NP_001100367 (A26-S158) ≥ 95%, as determined by reducing SDS-PAGE.
HY-P78556 IL-17A Protein, Rat (His) NP_001100367 (A26-S158) ≥ 95%, as determined by reducing SDS-PAGE.

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Inhibitory Antibodies (3)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P99280 Bimekizumab Antagonist 99.52% Unkown
HY-P9927 Secukinumab Inhibitor ≥99.20% Unkown
HY-P9924 Ixekizumab Inhibitor 99.00% Unkown

Clinical Phase

Bioactive Molecules (8)
Cat. No. Product Name Effect
Purity Phase
HY-177129 Simepdekinra Antagonist 99.05% Phase 2
HY-155830 Morcamilast Inhibitor 98.92% Phase 2
HY-153780 Navepdekinra Inhibitor 98.58% Phase 2
HY-103637 Vimirogant Inhibitor / Phase 2
HY-139206 LY3509754 Inhibitor 99.35% Phase 1
HY-107390 AX-024 Inhibitor 99.73% Phase 1
HY-107390A AX-024 hydrochloride Inhibitor 99.23% Phase 1
HY-139780 JNJ-61803534 Inhibitor 99.84% Phase 1
Inhibitory Antibodies (13)
Cat. No. Product Name Effect
Purity Phase
HY-P99335 Vunakizumab Inhibitor 95.00% Phase 4
HY-P99515 Xeligekimab Inhibitor 95.00% Phase 4
HY-P99563 Tibulizumab Inhibitor 98.86% Phase 3
HY-P99652 Gumokimab Inhibitor 98.95% Phase 3
HY-P99754 Netakimab Inhibitor 95.00% Phase 3
HY-P990761 Roconkibart 95.15% Phase 3
HY-P991595 HB-0017 Inhibitor / Phase 3
HY-P990741 Galvokimig 98.74% Phase 2
HY-P991091 COVA322 Inhibitor / Phase 2
HY-P991261 CJM-112 Inhibitor 99.65% Phase 2
HY-P991260 CNTO-6785 Inhibitor / Phase 2
HY-P991725 Velvakiment Inhibitor / Phase 2
HY-P991263 SCH-900117 Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (58)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-15826 SGC-CBP30 Inhibitor 99.83% Unkown
HY-P1924 IRBP(651-670) human, mouse Activator 99.64% Unkown
HY-101913 IL-17A antagonist 1 Antagonist 99.74% Unkown
HY-141692 IL-17 modulator 4 Modulator 98.19% Unkown
HY-P3450 Erepdekinra Antagonist 98.63% Unkown
HY-N0902 Dihydrosanguinarine Inhibitor 99.98% Unkown
HY-N3029 Noreugenin Inhibitor 99.42% Unkown
HY-119464 MRL-871 Agonist 99.11% Unkown
HY-147128 PY109 Agonist 99.15% Unkown
HY-101915 IL-17A antagonist 3 Antagonist 99.25% Unkown
HY-141692B (R)-IL-17 modulator 4 99.56% Unkown
HY-145429 IL-17A modulator-2 Modulator 98.44% Unkown
HY-145430 IL-17A modulator-1 Modulator 98.80% Unkown
HY-169853 M351-0056 99.48% Unkown
HY-183326 Isosorbide di-(methyl fumarate) Activator 99.87% Unkown
HY-103637A Vimirogant hydrochloride Inhibitor 98.39% Unkown
HY-139686 IL-17A inhibitor 2 Inhibitor 99.86% Unkown
HY-164826 Acetyl zingerone 99.34% Unkown
HY-155244 12R-LOX-IN-2 Inhibitor 99.85% Unkown
HY-133552 RORγt Inverse agonist 10 Antagonist 99.13% Unkown
HY-N11768 4-Methoxylonchocarpin Inhibitor 98.0% Unkown
HY-W145695 Chitoheptaose ≥98.0% Unkown
HY-128353 ROR agonist-1 Antagonist / Unkown
HY-141692A IL-17 modulator 4 sulfate Modulator / Unkown
HY-126252 A-9758 Inhibitor / Unkown
HY-130243 RORγt Inverse agonist 6 Antagonist 98.97% Unkown
HY-133128 FM26 Antagonist / Unkown
HY-142939 RORγt modulator 4 Modulator / Unkown
HY-148272 IL-17A modulator-3 Modulator 99.37% Unkown
HY-153276 Androgen receptor-IN-5 Inhibitor / Unkown
HY-155243 12R-LOX-IN-1 Inhibitor / Unkown
HY-158159 IL17A-IN-1 Inhibitor / Unkown
HY-162490 TF-S14 Inhibitor / Unkown
HY-168084 IL-17-IN-1 Inhibitor / Unkown
HY-168971 Paeoniflorin-6′-O-benzene sulfonate / Unkown
HY-169007 STAT3-IN-34 Inhibitor / Unkown
HY-169306 IL-17A inhibitor 4 Inhibitor / Unkown
HY-170611 IL-17-IN-3 Inhibitor / Unkown
HY-172806 PARP14 inhibitor 1 Inhibitor / Unkown
HY-178714 JNJ627 Inhibitor / Unkown
HY-179113 IL-17A-IN-5 Inhibitor / Unkown
HY-180608 TCR-IN-1 Inhibitor / Unkown
HY-181826 IL-17-IN-6 Inhibitor / Unkown
HY-181827 IL-17-IN-7 Inhibitor / Unkown
HY-182795 Colchicine derivative-1 / Unkown
HY-183370 JAK2/STAT3-IN-2 Inhibitor / Unkown
HY-183548 XW-17 Ligand / Unkown
HY-184385 PI3K/AKT/JAK2-IN-1 Inhibitor / Unkown
HY-N13251 Verbena Extract / Unkown
HY-N8529 Eupalestin Inhibitor / Unkown
HY-P1924A IRBP(651-670) human, mouse TFA Activator / Unkown
HY-RS06695 IL17A Human Pre-designed siRNA Set A / Unkown
HY-RS06696 Il17a Mouse Pre-designed siRNA Set A / Unkown
HY-RS06697 Il17a Rat Pre-designed siRNA Set A / Unkown
HY-RS06701 IL17F Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-174633 Human IL17A mRNA / Unkown
HY-N0976 1,11b-Dihydro-11b-hydroxymedicarpin Activator / Unkown
HY-N12481 Cephalandole B / Unkown
Inhibitory Antibodies (12)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P990222 Anti-Mouse/Rat IL-17A Antibody (17F3) Inhibitor 99.41% Unkown
HY-P9927A Secukinumab (Anti-Human IL-17A) Antagonist 98.31% Unkown
HY-P99424 Afasevikumab Inhibitor 95% Unkown
HY-P991797 Anti-Mouse IL-17A Antibody (BZN035) Inhibitor 97.90% Unkown
HY-P991035 Turenkibart Inhibitor 99.12% Unkown
HY-P99310 Perakizumab Inhibitor 99.79% Unkown
HY-P990973 Betinukibart Inhibitor / Unkown
HY-P991116 Amdokitug 95.696% Unkown
HY-P991129 Crusekitug Ligand 97.949% Unkown
HY-P992101 Aritinercept Inhibitor 99.9% Unkown
HY-P992045 HZD37-5 Inhibitor / Unkown
HY-P990252 Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Il17a NCBI NCBI:3605